News & Updates
Showing Oncology articles
Showing
China experience: Treatment decisions in post-neoadjuvant setting for HER2+ eBC
Neoadjuvant therapy for HER2-positive (HER2+) early-stage breast cancer (eBC) has improved survival outcomes. At a webinar hosted by the Cancer Information Charity Foundation, Professor Jian Zhang from the Fudan University Cancer Hospital, China, reviewed the current status of neoadjuvant BC treatment in China, discussed postoperative treatment approaches in patients not achieving pathological complete response (pCR), and explained how extended adjuvant therapy with the pan-HER inhibitor neratinib can mitigate risk of recurrence.
Toripalimab consolidation after cCRT signals PFS and OS benefits in Chinese patients with LS-SCLC
A randomized, multicentre, phase II trial reports signals of improved progression-free survival (PFS) and overall survival (OS) with toripalimab consolidation after concurrent chemoradiotherapy (cCRT) in Chinese patients with limited-stage (LS) small-cell lung cancer (SCLC).
Sacituzumab tirumotecan still effective in pretreated metastastic TNBC despite dose modification
A detailed safety analysis of the phase III, multicenter, open-label, randomized, controlled OptiTROP-Breast01 trial suggests that sacituzumab tirumotecan (sac-TMT) has a manageable safety profile and that adverse events (AEs) can be effectively managed through dose modification and appropriate supportive care without compromising its efficacy in previously treated metastatic triple-negative breast cancer (mTNBC).
Sacituzumab govitecan plus pembrolizumab no better than monotherapy in metastatic NSCLC
Combination treatment with sacituzumab govitecan (SG) and pembrolizumab has resulted in a numerically longer progression-free survival (PFS) compared with pembrolizumab alone in patients with previously untreated metastatic nonsmall-cell lung cancer (NSCLC), but the difference did not reach statistical significance, according to the phase III EVOKE-03/KEYNOTE D46 study.